Legal & General Group Plc Purchases 2,065 Shares of Medpace Holdings, Inc. $MEDP

Legal & General Group Plc boosted its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 4.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 44,082 shares of the company’s stock after purchasing an additional 2,065 shares during the period. Legal & General Group Plc owned about 0.16% of Medpace worth $24,759,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in the company. BOKF NA increased its holdings in Medpace by 0.8% during the 3rd quarter. BOKF NA now owns 2,542 shares of the company’s stock worth $1,307,000 after purchasing an additional 20 shares in the last quarter. Valeo Financial Advisors LLC increased its holdings in Medpace by 5.0% during the 4th quarter. Valeo Financial Advisors LLC now owns 444 shares of the company’s stock worth $249,000 after purchasing an additional 21 shares in the last quarter. HighPoint Advisor Group LLC increased its holdings in Medpace by 2.8% during the 3rd quarter. HighPoint Advisor Group LLC now owns 810 shares of the company’s stock worth $416,000 after purchasing an additional 22 shares in the last quarter. Kaufman Rossin Wealth LLC increased its holdings in Medpace by 3.4% during the 4th quarter. Kaufman Rossin Wealth LLC now owns 795 shares of the company’s stock worth $447,000 after purchasing an additional 26 shares in the last quarter. Finally, Berkeley Inc boosted its stake in shares of Medpace by 1.0% during the 4th quarter. Berkeley Inc now owns 2,694 shares of the company’s stock worth $1,513,000 after buying an additional 27 shares during the last quarter. Institutional investors own 77.98% of the company’s stock.

Insider Transactions at Medpace

In other Medpace news, President Jesse J. Geiger sold 31,707 shares of the firm’s stock in a transaction that occurred on Tuesday, March 17th. The shares were sold at an average price of $455.30, for a total transaction of $14,436,197.10. Following the completion of the sale, the president directly owned 15,000 shares in the company, valued at $6,829,500. This trade represents a 67.88% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 20.50% of the stock is owned by company insiders.

Key Stories Impacting Medpace

Here are the key news stories impacting Medpace this week:

• Negative Sentiment: Multiple law firms, including Bronstein, Gewirtz & Grossman, Faruqi & Faruqi, The Gross Law Firm, Rosen, Schall, Pomerantz, and others, issued updates this week about a pending class-action lawsuit against Medpace and reminded shareholders of upcoming lead-plaintiff deadlines, keeping legal risk in focus for the stock. Article Title
• Neutral Sentiment: The latest notices do not add new operational or financial guidance from Medpace; they mainly reiterate the same securities-fraud allegations and court deadline, so the immediate market impact is likely driven more by headline risk than by fundamentals. Article Title
• Neutral Sentiment: Short-interest data released alongside the legal headlines showed no meaningful borrowable shares reported, suggesting the move in MEDP is being driven by news flow rather than a clear short-selling signal.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the stock. BMO Capital Markets reduced their price objective on shares of Medpace from $460.00 to $400.00 and set a “market perform” rating for the company in a research note on Friday, April 24th. Jefferies Financial Group upgraded shares of Medpace from a “hold” rating to a “buy” rating and set a $560.00 price objective for the company in a research note on Friday, February 13th. Royal Bank Of Canada reduced their price objective on shares of Medpace from $522.00 to $484.00 and set an “outperform” rating for the company in a research note on Friday, April 24th. Robert W. Baird reduced their price objective on shares of Medpace from $565.00 to $477.00 and set an “outperform” rating for the company in a research note on Friday, April 24th. Finally, TD Cowen upgraded shares of Medpace from a “sell” rating to a “hold” rating and reduced their price objective for the stock from $462.00 to $419.00 in a research note on Wednesday, February 18th. Four investment analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $467.08.

Medpace Stock Performance

Shares of NASDAQ:MEDP opened at $447.11 on Monday. Medpace Holdings, Inc. has a 52-week low of $291.28 and a 52-week high of $628.92. The company has a market capitalization of $12.77 billion, a P/E ratio of 28.10, a price-to-earnings-growth ratio of 2.27 and a beta of 1.18. The company has a 50-day simple moving average of $457.47 and a 200 day simple moving average of $513.36.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings data on Wednesday, April 22nd. The company reported $4.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.74 by $0.54. The firm had revenue of $706.60 million during the quarter, compared to the consensus estimate of $697.82 million. Medpace had a net margin of 17.19% and a return on equity of 120.89%. The business’s revenue for the quarter was up 26.5% compared to the same quarter last year. During the same period last year, the business posted $3.67 earnings per share. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. As a group, equities analysts forecast that Medpace Holdings, Inc. will post 17.04 earnings per share for the current year.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.